Chilton Investment Co. LLC lifted its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 6.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 113,864 shares of the medical instruments supplier’s stock after acquiring an additional 7,052 shares during the period. Chilton Investment Co. LLC’s holdings in Becton Dickinson and were worth $24,374,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Westwood Holdings Group Inc. boosted its position in Becton Dickinson and by 24.2% in the second quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock valued at $206,136,000 after buying an additional 205,721 shares during the last quarter. Colony Group LLC boosted its position in Becton Dickinson and by 2.1% in the second quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after buying an additional 239 shares during the last quarter. State Street Corp boosted its position in Becton Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after buying an additional 342,873 shares during the last quarter. Peapack Gladstone Financial Corp boosted its position in Becton Dickinson and by 1.3% in the second quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after buying an additional 453 shares during the last quarter. Finally, Zions Bancorporation boosted its position in Becton Dickinson and by 23.7% in the third quarter. Zions Bancorporation now owns 10,718 shares of the medical instruments supplier’s stock valued at $2,100,000 after buying an additional 2,050 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.
A number of equities research analysts recently commented on BDX shares. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Wells Fargo & Co reiterated a “positive” rating and issued a $235.00 target price (up previously from $225.00) on shares of Becton Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank of Canada reiterated a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Morgan Stanley upped their target price on Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $237.27.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the previous year, the company posted $2.33 earnings per share. Becton Dickinson and’s revenue for the quarter was up 5.4% on a year-over-year basis. equities research analysts predict that Becton Dickinson and Co will post 10.95 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.38%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is presently 229.01%.
COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Shares Bought by Chilton Investment Co. LLC” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://stocknewstimes.com/2018/02/11/becton-dickinson-and-co-bdx-shares-bought-by-chilton-investment-co-llc.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.